Beyondspring Stock

Beyondspring Enterprise Value

The Enterprise Value (EV) of Beyondspring (BYSI) as of Sep 4, 2026 is 49.30 M USD. In the previous year, Enterprise Value (EV) was 44.22 M USD — a change of 11.49% (higher).

Enterprise Value

49.30 MUSD

YoY

11.49%

Last updated:

Enterprise Value (EV) of Beyondspring is 2026 49.30 M USD. Enterprise Value (EV) of Beyondspring was 2025 44.22 M USD. It decreases by 11.49% higher compared to the previous year.

The Beyondspring Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2017
21.67 M USD
Jan 1, 2018
48.34 M USD
Jan 1, 2019
17.76 M USD
Jan 1, 2020
-55.14 M USD
Jan 1, 2021
-18.57 M USD
Jan 1, 2022
14.96 M USD
Jan 1, 2023
44.22 M USD
Jan 1, 2024
49.30 M USD
The Beyondspring Enterprise Value history
YEAREnterprise ValueYoY
49.30 MUSD+11.49%
44.22 MUSD+195.66%
14.96 MUSD-180.53%
-18.57 MUSD-66.32%
-55.14 MUSD-410.55%
17.76 MUSD-63.26%
48.34 MUSD+123.05%
21.67 MUSD-46.82%
40.75 MUSD-2.60%
41.84 MUSD-22.98%
54.32 MUSD
Access this data via the Eulerpool API

Beyondspring Stock analysis

What does Beyondspring do? Beyondspring Inc is a globally operating biopharmaceutical company dedicated to the development of innovative cancer drugs. The company was founded in 2014 in New York City and today Beyondspring is based in New York and Shanghai. The founding of Beyondspring aimed to bring innovative cancer therapies to market that provide better treatment outcomes for patients. The company particularly focuses on a combination of proven therapeutic approaches and innovative technology, aiming to take a leading role in the oncology industry. Beyondspring focuses on the development of highly effective cancer therapies based on two platform technologies: protein engineering and immuno-oncology. The company is searching for substances that can strengthen the body's immune system and attack cancer cells. At the core of its business operations is the product Plinabulin. This is a novel cyclic peptide drug that is capable of activating the immune system and destroying cancer cells. The drug has been tested in multiple clinical trials and has shown promising results, particularly in breast cancer and lung cancer. In addition to product development, Beyondspring is also involved in the market development and commercialization of cancer drugs. The company works closely with hospitals, doctors, and other healthcare stakeholders to promote the use of Plinabulin and improve patient care. Beyondspring specializes in various types of cancer, such as lung cancer, breast cancer, and leukemia, where Plinabulin can be used. The company strives to constantly expand its product portfolio to explore additional indications. Beyondspring's business model relies on close collaboration with industry partners and the establishment of a global network. The company collaborates with leading research institutions and universities and continuously invests in the development of innovative technologies. The goal of Beyondspring is to provide cancer patients worldwide with access to innovative and highly effective treatment options. To achieve this, the company collaborates with regulatory authorities to expedite the approval of new drugs. Overall, Beyondspring is characterized by a highly dynamic and future-oriented business model. With its focus on innovative cancer therapies and the continuous expansion of its portfolio, the company has already established a strong position in the industry. In the future, Beyondspring will continue to expand its global presence and broaden its product range to provide cancer patients with the best possible treatment outcomes. Beyondspring is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beyondspring stock

Enterprise Value (EV) of Beyondspring is 49.30 M USD in 2026.

Enterprise Value (EV) of Beyondspring changed from 44.22 M USD to 49.30 M USD, representing a 11.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Beyondspring since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Beyondspring with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Beyondspring

All Key Metrics — Beyondspring